ArticleISRN gastroenterology2012
Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions.
Article in ISRN gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors.BioMed research international · 2014Trial
- Article
- Article
- Huge Gastrointestinal Stromal Tumor (GIST) in Upper Gastrointestinal Masquerade Anaemia.Cureus · 2024Article
- Article
- Gastrointestinal Stromal Tumor Masquerading As Acute Decompensated Heart Failure: A Challenging Diagnosis.Cureus · 2023Article
- Primary extragastrointestinal stromal tumor of the prostate: review of the literature and case report.Annals of medicine and surgery (2012) · 2023Article
- An unusual and life-threatening presentation of a large GIST.International journal of surgery case reports · 2022Article
- Effects of Endoscopic Submucosal Excavation With Non-Submucosal Injection on Stromal Tumors in Stomach.Frontiers in oncology · 2022Article
- Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.Journal of cellular and molecular medicine · 2020Article
- Endoscopic Removal of Gastrointestinal Stromal Tumors in the Stomach: A Single-Center Experience.Gastroenterology research and practice · 2019Article
- Gastric Schwannoma: A Case Report and Review of the Literature for Gastric Submucosal Masses Distinction.Case reports in medicine · 2018Article
- Lack of microsatellite instability in gastrointestinal stromal tumors.Oncology letters · 2017Article
- KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Small Bowel Gastrointestinal Stromal Tumor (GIST) Presenting with Liver Abscesses.Journal of gastrointestinal cancer · 2016Article
- Laparoscopy-assisted resection of CD117 and CD34 negative gastrointestinal tumor of stomach following tyrosine kinase inhibitor therapy.Medical journal, Armed Forces India · 2016Article
- Article
- Expression of CD117, DOG-1, and IGF-1R in gastrointestinal stromal tumours - an analysis of 70 cases from 2004 to 2010.Przeglad gastroenterologiczny · 2016Article
- Gastrointestinal stromal tumour presenting as palpable abdominal mass: A rare entity.World journal of gastrointestinal surgery · 2015Article
- Gastrointestinal stromal tumor of the adrenal gland:a case report and review of the literature.Endocrine pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal stromal tumor (GIST) is a nonepithelial, mesenchymal tumor first described by Mazur and Clark in 1983. Since then, its molecular biology has been studied in great detail. Special interest in the role of tyrosine kinase in its regulation has been the target by different drug research. Mutation in c-kit exons 9, 11, 13, 17 and PDGFRA mutation in exons 12, 14, 18 are responsible for activation of gene signaling system resulting in uncontrolled phosphorylation and tissue growth. However, 5 to 15% of GISTs does not harbor these mutations, which raises additional questions in another alternate signaling pathway mutation yet to be discovered. Diagnosis of GISTs relies heavily on KIT/CD117 immunohistochemical staining, which can detect most GISTs except for a few 3% to 5% that harbors PDGFRA mutation. Newer staining against PKC theta and DOG-1 genes showed promising results but are not readily available. Clinical manifestation of GISTs is broad and highly dependent on tumor size. Surgery still remains the first-line treatment for GISTs. The advancement of molecular biology has revolutionized the availability of newer drugs, Imatinib and Sunitinib. Together with its advancement is the occurrence of Imatinib/Sunitinib drug resistance. With this, newer monoclonal antibody drugs are being developed and are undergoing clinical trials to hopefully improve survival in patients with GISTs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.